EVISTA(generic)

On April, 12th the company «Eli Lilly» declared preliminary results of research Raloxifene Use of The Heart Trial (RUTH), large-scale platsebo-supervised research which spent for the purpose of definition, whether reduces reception Evista® (raloxifene a hydrochloride) risk of development of an ischemic heart trouble (IBS) and invasive a cancer of a lung at women in the posmenopausal period with diseases of cardiovascular system or high risk of development IBS. (далее…)